The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study

Progress in Neuro-psychopharmacology & Biological Psychiatry
Jihyung HongJacqueline Brown

Abstract

Relapse in schizophrenia is one of the greatest burdens of the illness. To estimate the costs associated with relapse in a pan-European naturalistic setting. The SOHO study is a 3-year, prospective, observational study of 10,972 outpatients with schizophrenia across 10 European countries. The cost of resource use (inpatient stay, day care, psychiatrist visits and medication) for those who ever relapsed in three years was compared to those who never relapsed. One-year costs for both groups were also compared for a more stringent comparison. The analyses were adjusted for patient characteristics and took account of non-normality of the cost data by using a log-link function. UK unit costs were applied to resource use. The analysis was repeated after multiple imputation for missing data. Costs incurred by patients who ever relapsed ( pound14,055) during three years were almost double to those incurred by patients who never relapsed ( pound7417). 61% of the cost difference was accounted for by hospital stay. The impact of relapse was even greater in the 1-year cost comparison. Results from the additional analysis with imputed missing data remained largely consistent. Our findings confirm the significant economic burden of relapse, ...Continue Reading

References

Jan 1, 1995·Schizophrenia Bulletin·P J Weiden, M Olfson
Jan 1, 1995·International Clinical Psychopharmacology·M Lader
Jul 27, 2001·Journal of Health Economics·W G Manning, J Mullahy
Jan 5, 2002·The New England Journal of Medicine·John G CsernanskyUNKNOWN Risperidone-USA-79 Study Group
Feb 13, 2003·Acta Psychiatrica Scandinavica·J M HaroUNKNOWN SOHO Study Group
May 21, 2003·Acta Psychiatrica Scandinavica. Supplementum·J M HaroUNKNOWN SOHO Study Group
Jun 10, 2003·The Journal of Bone and Joint Surgery. British Volume·P Gaston, R W Marshall
Apr 2, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Stephen AlmondTraolach Brugha
Jul 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Diana PerkinsUNKNOWN HGDH Research Group
Jul 29, 2004·Schizophrenia Bulletin·Martin KnappJudit Simon
Aug 26, 2004·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Eduardo Pondé de SenaIrismar Reis de Oliveira
Jul 13, 2005·European Archives of Psychiatry and Clinical Neuroscience·Alp UçokAysun Genç
Aug 10, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Stephen M BeardEckart Rüther
Nov 18, 2006·Journal of Clinical Psychopharmacology·Josep Maria HaroUNKNOWN SOHO Study Group
Mar 21, 2007·Annals of General Psychiatry·Maurizio PompiliRoberto Tatarelli

❮ Previous
Next ❯

Citations

Aug 27, 2013·Applied Health Economics and Health Policy·Jan ZeidlerStephan Heres
Jan 11, 2013·BMC Psychiatry·Laurent BoyerMondher Toumi
Jun 27, 2012·International Journal of Psychiatry in Clinical Practice·Luis SanMario Peña
Dec 31, 2014·International Journal of Psychiatry in Clinical Practice·Luis SanMariano Villar
Sep 7, 2013·Journal of Medical Economics·Marie-Hélène LafeuilleMei Sheng Duh
Nov 1, 2010·International Journal of Psychiatry in Clinical Practice·Jose Manuel MontesJerónimo Saiz-Ruiz
Sep 29, 2015·Journal of Medical Economics·Thomas R EinarsonBasil G Bereza
Feb 19, 2010·Current Medical Research and Opinion·Deborah NichollJan Schadrack
Sep 20, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Anders GustavssonUNKNOWN CDBE2010Study Group
Jul 25, 2014·Human Psychopharmacology·Takefumi SuzukiMasaru Mimura
Feb 24, 2016·International Journal of Psychiatry in Clinical Practice·Dario CannavòEugenio Aguglia
Apr 8, 2016·International Journal of Psychiatry in Clinical Practice·Stefano PorcelliAlessandro Serretti
Aug 28, 2013·Schizophrenia Research·Wolfgang Gaebel, Mathias Riesbeck
Aug 16, 2016·Asian Journal of Psychiatry·Vanteemar S Sreeraj, Ganesan Venkatasubramanian
Oct 26, 2016·International Journal of Mental Health Nursing·Natisha SandsJulie Considine
Nov 1, 2016·European Archives of Psychiatry and Clinical Neuroscience·José María Pelayo-TeránRosa Ayesa-Arriola
Jun 18, 2014·The Cochrane Database of Systematic Reviews·Kaisa KauppiClive E Adams
Sep 22, 2017·PloS One·Sarah SullivanPenny Whiting
Feb 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Marie-Hélène LafeuillePatrick Lefebvre
Nov 30, 2011·International Journal of Psychiatry in Clinical Practice·Evgenia StefanopoulouAdam Huxley
Aug 18, 2016·JBI Database of Systematic Reviews and Implementation Reports·Nisakorn PothimasThidarat Kanungpiarn
May 24, 2017·PharmacoEconomics·Mark Pennington, Paul McCrone
Mar 15, 2016·International Clinical Psychopharmacology·Larry AlphsIbrahim Turkoz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here